Navigation Links
Burrill & Company Announces Promotions
Date:4/9/2009

SAN FRANCISCO, April 9 /PRNewswire/ -- Burrill & Company, a San Francisco based global leader in the life sciences with principal activities in Venture Capital, Private Equity, Merchant Banking and Media, is pleased to announce the following staff promotions:

Tiba Aynechi to Director, Merchant Banking

Garrett Vygantas, Director, Venture Capital

Neel Patel to Senior Associate, Merchant Banking

Tiba Aynechi joined Burrill Merchant Banking in 2006 following an internship in the Venture Group. Previously, Tiba was a postdoctoral fellow at the University of California, San Francisco, developing computational models for drug discovery. She received her Ph.D. from the Graduate Group in Biophysics at the University of California, San Francisco.

Garrett Vygantas - Before joining Burrill in 2006, Garrett was with Genentech's Market Planning Group where he focused on the commercialization and launch of Lucentis for the treatment of wet age-related macular degeneration. Dr. Vygantas completed his Transitional Residency at the University of Pennsylvania and holds M.D. and MBA degrees from Georgetown University. He is a co-founder and interim CEO of NewBridge Pharmaceuticals and serves on its Board of Directors. He is a Board Observer of Nora Therapeutics, Proventys, Ikano Therapeutics, ProteoGenix, and NanoVasc.

Neel Patel has broad advisory experience across life sciences coupled with functional experience in post-merger integration, turnaround management, operations and strategic planning. Neel was a management consultant with A.T. Kearney where he focused on strategy and operations consulting. He also worked in business development at Roche Diagnostics. He has an MBA from the University of Chicago Graduate School of Business.

"Our Merchant Banking and Venture Capital Practices continue to perform very well despite the difficult economic climate that we are currently facing. The promotions are reflective of the excellent contributions that these three individuals have made," said, G. Steven Burrill, CEO, Burrill & Company.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the Burrill Report (www.burrillreport.com), which tracks the progress of the global biotechnology industry; the Burrill Report Weekly Brief, and annual "State of the Industry" report the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd report on the industry. This book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond (www.burrillandco.com/Biotech2009)


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
2. Biotech Finishes on a High in August, Burrill Report Says
3. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
4. New Sports Supplement Company to Partner with Indus Biotech
5. Sonic Innovations Celebrates Companys First Receiver-In-Canal Hearing Aid
6. Edmond Scientific Company Demonstrates RHIO/HIE Data Security and Privacy Solution for the NHIN at Annual HIMSS Conference, Chicago 09
7. Kashi Company Expands With New Island Vanilla(TM) Biscuit Cereal
8. TrinityCare Senior Living, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel
9. Alivemax -- A Company Releasing Supplemental Products That Will Uplift the Health, Appearance, and Confidence of Others Around the Globe
10. Carriage Services Updates Company & Investment Profile
11. Anthem Blue Cross and Blue Shield, Eli Lilly and Company Establish Coalition to Help Improve the Health of Indiana Residents with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology: